β-Lactamases and β-lactamase inhibitors

International Journal of Antimicrobial Agents

Volumn 12, Issue SUPPL. 1, 1999, Pages

  Williams, J D ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Resistance enzymes; Lactamase; Lactamase inhibitors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN; TIMENTIN;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; DRUG CLASSIFICATION; DRUG DEGRADATION; DRUG RESEARCH; ENZYME ACTIVITY; HISTORY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, MICROBIAL; ENZYME INHIBITORS;

EID: 0032815029     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00085-0     Document Type: Article

References (16)

1. Chambers HF, Neu HC. Penicillins. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995:233-46.
2. Abraham EP, Chain E. Nature 1940;146:837.
3. Kirby WMM. J Clin Invest 1945;24:170-4.
4. Moellering RC. Meeting the challenges of β-lactamases. J Antimicrob Chemother 1993;31(Suppl A): 1-8.
5. Sykes RB, Matthew M. The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics. Antimicrob Agents Chemother 1976;2:115-57.
6. Sanders CC, Sanders WE. β-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992;15:824-39.
7. Garau J. Beta-lactamases: current situation and clinical importance. Intensive Care Med 1994;20:85-9.
8. Summanen P, Baron EJ, Citron DM, Wadsworth Anaerobic Bacteriology Manual. Belmont, CA: Star Publishing Co., 1993; 1.
9. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
10. Pontani D, Washton H, Bouchillon A, et al. Susceptibility of European respiratory tract isolates to trovafloxacin ciprofloxacin clarithromycin azithromycin and ampicillin. Eur J Clin Microbiol Infect Dis 1998;17:413-9.
11. Felmingham D, Gruneberg RN. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens 1992-1993: The Alexander Project. J Antimicrob Chemother 1996;38(Suppl A):1-57.
12. Liu PYF, Gur D, Hall LMC, et al. Survey of the prevalance of beta-lactamases amongst 1000 gram-negative bacilli isolated con secutively at the Royal London Hospital. J Antimicrob Chemother 1992;30:429-47.
13. Wexler HM, Finegold SM. Antimicrobial resistance in Bacteroides. J Antimicrob Chemother 1987;19:143-6.
14. Moosdeen F. Impact of β-lactamases on the clinical use of β-lactam antibiotics. In: Viewpoints in Medicine, Countering Resistance due to β-lactamases. Worthing: Cambridge Medical Publications, 1996:6-11.
15. Chambers HF, Neu HC. Other β-lactam antibiotics. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995:264-72.
16. Cole M. Inhibitors of antibiotic inactivating enzymes. In: Williams JD, editor. Antibiotic Interactions. London Academic Press, 1979:99-131.